Alvotech Resubmits FDA Applications for Two Key Biosimilars, AVT05 and AVT06

summarizeSummary

Alvotech has resubmitted Biologics License Applications (BLAs) to the FDA for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar), addressing prior regulatory concerns and setting a six-month review timeline.

check_boxKey Events

• FDA Resubmission for AVT05 & AVT06

  Alvotech has resubmitted Biologics License Applications (BLAs) to the U.S. FDA for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab), and AVT06, a proposed biosimilar to Eylea® (aflibercept) 2 mg.

• Regulatory Hurdles Addressed

  The resubmissions follow Alvotech's response to the FDA's Post-Application Action Letter and observations from a routine cGMP surveillance FDA inspection at its Reykjavik manufacturing facility, completed in May 2026.

• Six-Month Review Expected

  The company expects the FDA to conduct a six-month review of the resubmitted applications, consistent with applicable regulatory timelines.

auto_awesomeAnalysis

This filing is highly important as Alvotech has successfully addressed the FDA's Post-Application Action Letter and cGMP inspection observations, allowing for the resubmission of two critical biosimilar applications for the U.S. market. The potential approval of AVT05 (golimumab) and especially AVT06 (aflibercept, biosimilar to Eylea, a blockbuster drug) would significantly boost Alvotech's revenue potential and market position, providing a clear path for growth following recent financial reports. The expected six-month review period provides a concrete timeline for investors to anticipate potential approvals.